Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2003 Aug;40(8):591–596. doi: 10.1136/jmg.40.8.591

Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer

P Watson 1, S Narod 1, R Fodde 1, A Wagner 1, J Lynch 1, S Tinley 1, C Snyder 1, S Coronel 1, B Riley 1, Y Kinarsky 1, H Lynch 1
PMCID: PMC1735553  PMID: 12920070

Abstract

Context: In hereditary cancer syndrome families with an identified cancer associated mutation, mutation testing changes the carrier risk status of the tested person and may change the carrier risk status of relatives.

Objective: This study aimed to describe the change in the distribution of carrier risk status resulting from testing in hereditary breast-ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) families.

Design: This was an observational cohort study.

Patients: The cohort included members of 75 HBOC and 47 HNPCC families. Of the 10 910 cohort members, 1408 were tested for a mutation and learned their test results.

Outcome measure: Carrier risk for all cohort members was assessed before and after mutation testing.

Results: There was a change in carrier risk status in 2906 subjects after testing of 1408 family members. The most common type of carrier risk change, from at risk to non-carrier status, accounted for 77% of the risk changes; 12% were a change to known carrier status from a lower risk. Sixty percent of persons with a carrier risk status change were not themselves tested; their risk status changed because of a relative's test result.

Conclusions: Carrier risk status changes from uncertainty to certainty (that is, to carrier or to non-carrier) account for 89% of risk changes resulting from testing. These risk changes affect cancer prevention recommendations, most commonly reducing their burden. Current practices do not ensure that untested family members are informed about changes in their carrier risk status which result from mutation testing of their relatives.

Full Text

The Full Text of this article is available as a PDF (217.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aktan-Collan K., Haukkala A., Mecklin J. P., Uutela A., Käriäinen H. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer. 2001 Aug 15;93(4):608–611. doi: 10.1002/ijc.1372. [DOI] [PubMed] [Google Scholar]
  2. Benkendorf J. L., Reutenauer J. E., Hughes C. A., Eads N., Willison J., Powers M., Lerman C. Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. Am J Med Genet. 1997 Dec 19;73(3):296–303. doi: 10.1002/(sici)1096-8628(19971219)73:3<296::aid-ajmg13>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  3. Berry Donald A., Iversen Edwin S., Jr, Gudbjartsson Daniel F., Hiller Elaine H., Garber Judy E., Peshkin Beth N., Lerman Caryn, Watson Patrice, Lynch Henry T., Hilsenbeck Susan G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 1;20(11):2701–2712. doi: 10.1200/JCO.2002.05.121. [DOI] [PubMed] [Google Scholar]
  4. Burke W., Petersen G., Lynch P., Botkin J., Daly M., Garber J., Kahn M. J., McTiernan A., Offit K., Thomson E. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 1997 Mar 19;277(11):915–919. [PubMed] [Google Scholar]
  5. Hartmann L. C., Sellers T. A., Schaid D. J., Frank T. S., Soderberg C. L., Sitta D. L., Frost M. H., Grant C. S., Donohue J. H., Woods J. E. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001 Nov 7;93(21):1633–1637. doi: 10.1093/jnci/93.21.1633. [DOI] [PubMed] [Google Scholar]
  6. Julian-Reynier C., Eisinger F., Chabal F., Lasset C., Noguès C., Stoppa-Lyonnet D., Vennin P., Sobol H. Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors. Am J Med Genet. 2000 Sep 4;94(1):13–18. doi: 10.1002/1096-8628(20000904)94:1<13::aid-ajmg4>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  7. Lynch H. T. Family information service and hereditary cancer. Cancer. 2001 Feb 15;91(4):625–628. doi: 10.1002/1097-0142(20010215)91:4<625::aid-cncr1044>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  8. Lynch H. T. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum. 1996 Jan;39(1):109–110. doi: 10.1007/BF02048279. [DOI] [PubMed] [Google Scholar]
  9. Lynch H. T., Lynch J. F., Rubinstein W. S. Prophylactic mastectomy: obstacles and benefits. J Natl Cancer Inst. 2001 Nov 7;93(21):1586–1587. doi: 10.1093/jnci/93.21.1586. [DOI] [PubMed] [Google Scholar]
  10. Lynch H. T., Watson P., Shaw T. G., Lynch J. F., Harty A. E., Franklin B. A., Kapler C. R., Tinley S. T., Liu B. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part I: Studies of cancer in families. Cancer. 1999 Dec 1;86(11 Suppl):2449–2456. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2449::aid-cncr1>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  11. Lynch H. T., Watson P., Shaw T. G., Lynch J. F., Harty A. E., Franklin B. A., Kapler C. R., Tinley S. T., Liu B., Lerman C. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer. 1999 Dec 1;86(11 Suppl):2457–2463. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2457::aid-cncr2>3.3.co;2-9. [DOI] [PubMed] [Google Scholar]
  12. Lynch H. T., Watson P., Tinley S., Snyder C., Durham C., Lynch J., Kirnarsky Y., Serova O., Lenoir G., Lerman C. An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet. 1999 Mar;109(2):91–98. doi: 10.1016/s0165-4608(98)00165-4. [DOI] [PubMed] [Google Scholar]
  13. Lynch H. T., de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999 Nov;36(11):801–818. [PMC free article] [PubMed] [Google Scholar]
  14. Lynch Henry T., Snyder Carrie L., Lynch Jane F., Riley Bronson D., Rubinstein Wendy S. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol. 2003 Feb 15;21(4):740–753. doi: 10.1200/JCO.2003.05.096. [DOI] [PubMed] [Google Scholar]
  15. Rebbeck Timothy R., Lynch Henry T., Neuhausen Susan L., Narod Steven A., Van't Veer Laura, Garber Judy E., Evans Gareth, Isaacs Claudine, Daly Mary B., Matloff Ellen. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 20;346(21):1616–1622. doi: 10.1056/NEJMoa012158. [DOI] [PubMed] [Google Scholar]
  16. Smith Ken R., Zick Cathleen D., Mayer Robert N., Botkin Jeffery R. Voluntary disclosure of BRCA1 mutation test results. Genet Test. 2002 Summer;6(2):89–92. doi: 10.1089/10906570260199339. [DOI] [PubMed] [Google Scholar]
  17. Veatch R. M. Consent, confidentiality, and research. N Engl J Med. 1997 Mar 20;336(12):869–870. doi: 10.1056/NEJM199703203361209. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES